Expression of Molecular Markers Associated with Tenosynovial Giant Cell Tumours and Bone Destruction: A Systematic Review
Open Access
- 15 March 2026
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (6) , 2238
Abstract
Background/Objectives: Tenosynovial giant cell tumours (TGCT) are a group of mesenchymal tumours involving the synovium, bursae, and tendon sheaths, comprising two subtypes: nodular and diffuse. Although predominantly benign, diffuse forms can be locally aggressive, resulting in bone destruction. The pathogenesis of TGCTs is still poorly understood. The aim of this study was to systematically review the current literature on the factors, mechanisms, and markers involved in TGCT disease, focussing on their potential role in bone destruction. Methods: This systematic review was conducted using the PRISMA guidelines. A search was performed using PubMed, Scopus, and Cochrane Library, and all original scientific research into mechanisms/pathways/signalling involving TGCTs was included. Results: After the review process, 51 studies were included for data extraction. Extracted data included authorship, publication year, patient numbers and aetiology (nTGCT/dTGCT), demographics, investigative methods, and studied biological factors, mechanisms, and markers. Cross-tabulation of reported elements revealed 159 unique factors, with most appearing only once. Eight elements were reported five or more times: CSF1, CD68, Ki-67, MMP9, CD163, TRAP, TNF-α, and IL-1β. Although representing just 5% of all identified factors, these appeared in 69% of the included studies, highlighting their prominence in the literature. Conclusions: Apart from the well-known osteoclastogenesis factor CSF1, inflammatory cytokines (TNF-α and IL-1β) and monocyte–macrophage lineage makers (CD68, CD163) are signalling pathways key to TGCT disease progression and associated bone destruction.Keywords
Funding Information
- Royal College of Surgeons of Edinburgh (2024)
- Leicester Hospitals Charity Sarcoma Fund (APP8971)
- NIHR Leicester Biomedical Research Centre (NIHR203327)
This publication has 120 references indexed in Scilit:
- Single‐Cell Analysis Clarifies Pathological Heterogeneity in Tenosynovial Giant Cell Tumor and Identifies Biomarkers for Predicting Disease RecurrenceAdvanced Science, 2025
- Mapping and Analysis of Protein and Gene Profile Identification of the Important Role of Transforming Growth Factor Beta in Synovial Invasion in Patients With Pigmented Villonodular SynovitisArthritis & Rheumatology, 2024
- Detection of CSF1 rearrangements deleting the 3′ UTR in tenosynovial giant cell tumorsGenes, Chromosomes and Cancer, 2019
- Multi‐lineage differentiation and angiogenesis potentials of pigmented villonodular synovitis derived mesenchymal stem cells ‐ pathological implicationJournal of Orthopaedic Research, 2015
- Molecular identification of COL6A3‐CSF1 fusion transcripts in tenosynovial giant cell tumorsGenes, Chromosomes and Cancer, 2007
- Analysis of pigmented villonodular synovitis with genome‐wide complementary DNA microarray and tissue array technology reveals insight into potential novel therapeutic approachesArthritis & Rheumatism, 2006
- Different mechanisms of synovial hyperplasia in rheumatoid arthritis and pigmented villonodular synovitis: The role of telomerase activity in synovial proliferationArthritis & Rheumatism, 1999
- Giant cell tumor of the tendon sheath: A retrospective study of 28 casesJournal of Surgical Oncology, 1998
- EXPRESSION OF PARATHYROID HORMONE (PTH)-RELATED PEPTIDE (PTHrP) AND PTH/PTHrP RECEPTOR IN GIANT CELL TUMOUR OF TENDON SHEATHThe Journal of Pathology, 1996
- Trisomy 5 and trisomy 7 are nonrandom aberrations in pigmented villonodular synovitis: Confirmation of trisomy 7 in uncultured cellsGenes, Chromosomes and Cancer, 1992